Jin Cheng

Title: Jin Cheng - Innovator in Vascular Treatment Technologies

Introduction

Jin Cheng is a notable inventor based in San Jose, California, recognized for his contributions to medical technology. He holds a patent that addresses significant challenges in the treatment of vascular disorders. His innovative approach combines drug delivery systems with implantable medical devices, showcasing his expertise in the field.

Latest Patents

Jin Cheng's patent, titled "Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device," presents a drug-delivery system that includes at least 100 µg of everolimus and clobetasol. The ratio of everolimus to clobetasol is at least 10:1 by weight, ensuring that the amount of everolimus is significantly greater than that of clobetasol. This system can be utilized in stents and provides a method for treating restenosis or vulnerable plaque in blood vessels. The method involves locally administering a first drug from a specified group, including everolimus, and a second drug, clobetasol, in a defined ratio.

Career Highlights

Throughout his career, Jin Cheng has worked with prominent companies in the medical field, including Abbott Cardiovascular Systems, Inc. and ASML Netherlands B.V. His experience in these organizations has contributed to his development of innovative solutions for vascular treatments.

Collaborations

Jin Cheng has collaborated with esteemed colleagues such as Stephen R. Dugan and Gordon S. Stewart. These partnerships have likely enhanced his research and development efforts in the medical technology sector.

Conclusion

Jin Cheng's work exemplifies the intersection of innovation and healthcare, particularly in the treatment of vascular disorders. His patented drug-delivery system represents a significant advancement in medical technology, highlighting his role as a key inventor in this field.